Pharma improves reputation among German patient groups
A survey of 86 German patient groups suggests pharma’s reputation is improving in the country that has been wary of pharma in the past, with Amgen and Janssen leading the way.
Linda Banks
corporate reputation, German patient group, patient perspective, patient voice, pharma reputation
0 Comment
A survey of 86 German patient groups suggests pharma’s reputation is improving in the country that has been wary of pharma in the past, with Amgen and Janssen leading the way.
Disease Spotlight/ DMD Main/ eyeforpharma Barcelona 2015/ Patients/ Views and analysis
Linda Banks
DMD, Duchenne muscular dystrophy, patient perspective, patient voice, patients
0 Comment
Making sure everyone with DMD gets access to treatments and the ‘essential’ interventions that can make life worth living is key.
Disease Spotlight/ DMD Main/ Patients/ Views and analysis
Linda Banks
DMD, Duchenne muscular dystrophy, patient perspective, patient voice
0 Comment
Disease Spotlight/ DMD Main/ Patients/ Views and analysis
Linda Banks
DMD, Duchenne, Duchenne muscular dystrophy, patient centricity, patient perspective
0 Comment
Progress in health and social care in European countries is helping many boys with Duchenne muscular dystrophy (DMD) to extend their lives beyond what was once dreamed possible, and to take control of their lives as they grow up and become men.
Articles/ LHON Main/ Views and analysis
Linda Banks
eye disease, hereditary eye disease, LHON, LHON awareness, LHON Society, mitochondrial disease, patient perspective, patients, rare disease
0 Comment
Articles/ Rare diseases/ Views and analysis
Linda Banks
eye disease, gene therapy, inherited disease, patient perspective, rare disease, Spark Therapeutics
0 Comment
US FDA expert committee’s ‘yes’ could pave the way for a new generation of gene therapies for rare inherited eye disorders.
Articles/ Healthcare/ Rare diseases/ UK & Europe/ Views and analysis
Linda Banks
Deep Dive, patient centricity, patient perspective, patients, Rare diseases
0 Comment
Benefitting from insights from focus groups with rare disease patients.